Vyne Therapeutics Inc.
13F holders, Q3 2025 (September 30)3holders +1
1new positions
0sold out
$0.34avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, up 1 from Q2 2025. 1 opened new positions and 0 sold out. The largest holders were Staley Capital Advisers Inc. ($17K), Fortitude Family Office, LLC ($228) and Farther Finance Advisors, LLC ($5).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $228 |
| Exits | 0 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 680 shares bought, net +680 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Staley Capital Advisers Inc. | 0.00% | No change | 51,472 | $17K |
| Fortitude Family Office, LLC | 0.00% | New | 680 | $228 |
| Farther Finance Advisors, LLC | 0.00% | No change | 16 | $5 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.